{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Hepatitis C virus", "direct acting-antiviral", "drug interactions", "effectiveness", "safety"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "29325476", "DateCompleted": {"Year": "2018", "Month": "02", "Day": "15"}, "DateRevised": {"Year": "2021", "Month": "12", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2018", "Month": "01", "Day": "11"}], "Language": ["eng"], "ELocationID": ["10.1080/14740338.2018.1424829"], "Journal": {"ISSN": "1744-764X", "JournalIssue": {"Volume": "17", "Issue": "3", "PubDate": {"Year": "2018", "Month": "Mar"}}, "Title": "Expert opinion on drug safety", "ISOAbbreviation": "Expert Opin Drug Saf"}, "ArticleTitle": "Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.", "Pagination": {"StartPage": "235", "EndPage": "241", "MedlinePgn": "235-241"}, "Abstract": {"AbstractText": ["To explore the effectiveness and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir (OBV/PTV/r+DSV) for 12\u00a0weeks without ribavirin in adults with chronic HCV genotype 1b infection and compensated cirrhosis.", "Observational study of a prospective cohort of adult patients with HCV genotype 1b infection and compensated cirrhosis who received 12\u00a0weeks of OBV/PTV/r and DSV without ribavirin. Effectiveness was assessed by recording the percentage of patients achieving sustained virological response at week 12 post-treatment (SVR12). Safety outcomes were based on the incidence of adverse events.", "Seventy-eight patients were included. The SVR12 rate was 96.1% (95%CI 89.2-99.2). Adverse events were recorded in 78.0% of patients. Of these, 97.7% were grade 1/2. One patient discontinued treatment prematurely owing to adverse events. Eighty-six interactions were detected in 43 patients (55.1%). Overall, 81.4% of interactions required close monitoring, alteration of drug dosage, or timing of administration. In 7.0% of cases, the interactions arose from contraindications that required the suspension of the concomitant drug. In 11.6% of cases, medicinal plants or foods were withdrawn.", "The simplified regimen of OBV/PTV/r+DSV administered for 12\u00a0weeks is effective and safe in patients with chronic HCV genotype 1b infection and compensated cirrhosis. No adverse reactions related to drug-drug interactions were recorded."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Pharmacy Department , Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n , Madrid , Spain."}], "LastName": "Chamorro-de-Vega", "ForeName": "Esther", "Initials": "E"}, {"Identifier": ["0000-0003-3250-5022"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Pharmacy Department , Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n , Madrid , Spain."}], "LastName": "Gimenez-Manzorro", "ForeName": "Alvaro", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Pharmacy Department , Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n , Madrid , Spain."}], "LastName": "Rodriguez-Gonzalez", "ForeName": "Carmen-Guadalupe", "Initials": "CG"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Pharmacy Department , Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n , Madrid , Spain."}], "LastName": "Escudero-Vilaplana", "ForeName": "Vicente", "Initials": "V"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Pharmacy Department , Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n , Madrid , Spain."}], "LastName": "De Lorenzo-Pinto", "ForeName": "Ana", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "b Faculty of Pharmacy , Universidad Complutense de Madrid , Madrid , Spain."}], "LastName": "Iglesias-Peinado", "ForeName": "Irene", "Initials": "I"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Pharmacy Department , Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n , Madrid , Spain."}], "LastName": "Herranz-Alonso", "ForeName": "Ana", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Pharmacy Department , Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria del Hospital Gregorio Mara\u00f1\u00f3n , Madrid , Spain."}], "LastName": "Sanjurjo Saez", "ForeName": "Maria", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [], "CollectiveName": "GRUviC Study Group"}], "PublicationTypeList": ["Journal Article", "Observational Study"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Expert Opin Drug Saf", "NlmUniqueID": "101163027", "ISSNLinking": "1474-0338"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anilides"}, {"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Carbamates"}, {"RegistryNumber": "0", "NameOfSubstance": "Cyclopropanes"}, {"RegistryNumber": "0", "NameOfSubstance": "Lactams, Macrocyclic"}, {"RegistryNumber": "0", "NameOfSubstance": "Macrocyclic Compounds"}, {"RegistryNumber": "0", "NameOfSubstance": "Sulfonamides"}, {"RegistryNumber": "2302768XJ8", "NameOfSubstance": "ombitasvir"}, {"RegistryNumber": "56HH86ZVCT", "NameOfSubstance": "Uracil"}, {"RegistryNumber": "9DLQ4CIU6V", "NameOfSubstance": "Proline"}, {"RegistryNumber": "CKR7XL41N4", "NameOfSubstance": "2-Naphthylamine"}, {"RegistryNumber": "DE54EQW8T1", "NameOfSubstance": "dasabuvir"}, {"RegistryNumber": "HG18B9YRS7", "NameOfSubstance": "Valine"}, {"RegistryNumber": "O3J8G9O825", "NameOfSubstance": "Ritonavir"}, {"RegistryNumber": "OU2YM37K86", "NameOfSubstance": "paritaprevir"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "2-Naphthylamine"}, {"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": ["administration & dosage", "adverse effects"], "DescriptorName": "Anilides"}, {"QualifierName": ["administration & dosage", "adverse effects"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": ["administration & dosage", "adverse effects"], "DescriptorName": "Carbamates"}, {"QualifierName": [], "DescriptorName": "Cohort Studies"}, {"QualifierName": [], "DescriptorName": "Cyclopropanes"}, {"QualifierName": [], "DescriptorName": "Drug Interactions"}, {"QualifierName": [], "DescriptorName": "Drug Therapy, Combination"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Genotype"}, {"QualifierName": ["genetics"], "DescriptorName": "Hepacivirus"}, {"QualifierName": ["drug therapy", "virology"], "DescriptorName": "Hepatitis C, Chronic"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Lactams, Macrocyclic"}, {"QualifierName": ["drug therapy", "virology"], "DescriptorName": "Liver Cirrhosis"}, {"QualifierName": ["administration & dosage", "adverse effects"], "DescriptorName": "Macrocyclic Compounds"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Middle Aged"}, {"QualifierName": ["analogs & derivatives"], "DescriptorName": "Proline"}, {"QualifierName": [], "DescriptorName": "Prospective Studies"}, {"QualifierName": ["administration & dosage", "adverse effects"], "DescriptorName": "Ritonavir"}, {"QualifierName": ["administration & dosage", "adverse effects"], "DescriptorName": "Sulfonamides"}, {"QualifierName": [], "DescriptorName": "Treatment Outcome"}, {"QualifierName": ["administration & dosage", "adverse effects", "analogs & derivatives"], "DescriptorName": "Uracil"}, {"QualifierName": [], "DescriptorName": "Valine"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2018", "Month": "1", "Day": "13", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "2", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2018", "Month": "1", "Day": "13", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["29325476", "10.1080/14740338.2018.1424829"]}}]}